Advertisement

Advertisement

lung cancer

IO Strategies for Resectable NSCLC

This is Part 1 of New Directions in Nonmetastatic Non–Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Heather Wakelee, Tina Cascone, and Marina Garassino discuss immune checkpoint inhibitor strategies for resectable nonmetastatic non–small cell lung cancer (NSCLC). The patient is an active 68-year-old woman with a 70-pack-year smoking history. On screening computed tomography, she was found to have a 3.7-cm right upper lobe mass, which biopsy confirmed as adenocarcinoma. Further staging revealed uptake in a 10R node on positron-emission tomography, but no other suspicious sites.   In the conversation that follows, the faculty discuss the importance of completing staging prior to resection; how PD-L1 testing informs therapeutic strategies; and the role of neoadjuvant, perioperative, and adjuvant immune checkpoint inhibitor therapy in treating stage II/III NSCLC.

Lung Cancer
Immunotherapy

Real-World Data Show Impact of Immunotherapy in Populations Underrepresented in Lung Cancer Clinical Trials

New research published by Lee et al in JNCCN—Journal of the National Comprehensive Cancer Network found patients treated with first-line immunotherapy for advanced non–small cell lung cancer (NSCLC) had similar results in terms of overall survival, progression-free survival, and treatment duration, ...

Breast Cancer
Lung Cancer

Addition of SBRT to Standard-of-Care Systemic Therapy in Oligoprogressive Disease

In the phase II CURB trial reported in The Lancet, Chiaojung Jillian Tsai, MD, PhD, and colleagues found that the addition of stereotactic body radiotherapy (SBRT) to standard-of-care systemic therapy was associated with improved progression-free survival in the total study population of patients...

Lung Cancer

Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust Activity in Refractory Small Cell Lung Cancer

The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...

Lung Cancer

Phase III Trial Shows Novel Four-Drug Regimen Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...

Lung Cancer

ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC

A newly published guideline update from ASCO and Ontario Health provides evidence-based recommendations on the use of systemic therapy for small cell lung cancer (SCLC).1 Recommendations cover where novel agents fit in the treatment landscape, the management of disease in older patients with...

Lung Cancer

Neoadjuvant/Adjuvant Pembrolizumab in Resectable NSCLC

On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC).1 Supporting Efficacy Data Approval was based ...

Lung Cancer

EGFR-Mutated Advanced NSCLC: CNS Efficacy With Combination of Osimertinib and Chemotherapy

In a subgroup analysis from the phase III FLAURA2 trial reported in the Journal of Clinical Oncology, Pasi A. Jänne, MD, PhD, and colleagues found the combination of osimertinib and chemotherapy improved central nervous system (CNS) efficacy vs osimertinib alone in the first-line treatment of...

Lung Cancer

Advanced NSCLC: Adding Canakinumab to First-Line Chemoimmunotherapy

As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...

Lung Cancer
Issues in Oncology

Lung Nodule Program May Help Detect Cancer in Patients Age-Ineligible for Lung Cancer Screening

Researchers have found that adopting a Lung Nodule Program may increase early lung cancer detection in patients who are not eligible for lung cancer screening under existing age-eligibility criteria, according to a recent study published by Liao et al in the Journal of Thoracic Oncology. ...

Lung Cancer
Genomics/Genetics

Encorafenib Plus Binimetinib in Metastatic NSCLC With BRAF V600E Mutation

On October 11, 2023, the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) was approved for patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA...

Lung Cancer

American Cancer Society Releases Updated Lung Cancer Screening Guideline

Lung cancer incidence overall has been declining in the United States since 1992—and since 2006–2007 for both men and women by 2.7% annually and 1.1%, respectively—and overall mortality rates have declined in both men and women because of smoking cessation efforts and advances in therapy and early...

Lung Cancer

Expert Point of View: Upal Basu Roy, PhD, MPH

Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...

Lung Cancer

INCREASE Trial: Immunotherapy Plus Chemoradiotherapy Doubles Complete Pathologic Response Rate in NSCLC

The integration of immunotherapy with traditional chemoradiotherapy has significantly increased pathologic complete response rates in patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on...

Lung Cancer

Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC

Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...

Lung Cancer
Issues in Oncology

Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy

The unique public-private partnership that undergirded the Lung-MAP trial for almost a decade may serve as a model for future clinical research that is more rapid, innovative, and inclusive, according to a recent report published by Herbst et al in Clinical Cancer Research. Background The Lung-MAP...

Lung Cancer

Adding Tiragolumab to Atezolizumab and Chemotherapy in Previously Untreated Extensive-Stage SCLC

As reported in the Journal of Clinical Oncology by Charles M. Rudin, MD, PhD, and colleagues, the phase III SKYSCRAPER-02 trial showed no progression-free or overall survival benefit with the addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor tiragolumab to atezolizumab and...

Lung Cancer

Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC

In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...

Lung Cancer
Immunotherapy
Issues in Oncology

Toxicities Potentially Linked to Combination Immunotherapy for Mesothelioma

The combination of ipilimumab and nivolumab may result in a higher levels of toxicities in patients with unresectable pleural mesothelioma than was reported in the CheckMate 743 trial, according to a recent study published by McNamee et al in the Journal of Thoracic Oncology. Background Australia...

Lung Cancer

Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC

Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...

Lung Cancer
Issues in Oncology

Novel AI Model May Predict Nonsmokers at High Risk for Lung Cancer

An artificial intelligence (AI) model may be capable of using routine chest x-ray images to identify nonsmokers who may be at high risk for lung cancer, according to new findings presented by Walia et al at the Radiological Society of North American (RSNA) 2023 Scientific Assembly and Annual...

Lung Cancer

ALINA Trial: Anticancer Activity of Alectinib Reported in Earlier-Stage, ALK-Positive NSCLC

Treatment with the anaplastic lymphoma kinase (ALK) inhibitor alectinib significantly reduced the risk of recurrence or death by 76% (P < .0001) in patients with completely resected stage IB to IIIA ALK-positive non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy. This...

Lung Cancer

Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC

Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes with regimens incorporating the bispecific antibody amivantamab-vmjw for patients with advanced non–small...

Lung Cancer

PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset

In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with untreated non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)...

Lung Cancer
Issues in Oncology

Durvalumab May Offer Survival Benefit in Patients With NSCLC and Borderline Performance Status

The immune checkpoint inhibitor durvalumab may be safe and effective at improving overall survival in patients who have advanced or metastatic non–small cell lung cancer (NSCLC) and borderline performance status, according to a recent study published by Shaverdashvili et al in eClinicalMedicine....

Lung Cancer

Expert Point of View: Noemí Reguart, MD, PhD

Abstract discussant Noemí Reguart, MD, PhD, an oncologist at the Hospital Clinic Barcelona, underscored the “impressive” progression-free and overall survival results of the phase III ETER701 trial, which have “never been achieved before in extensive-stage small cell lung cancer.” According to Dr. ...

Lung Cancer

Phase III Trial Shows Novel Four-Drug Immunotherapy Regimen Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

The addition of anlotinib to immunochemotherapy has achieved the historically longest progression-free survival and overall survival in the first-line setting of extensive-stage small cell lung cancer, according to data presented at the International Association for the Study of Lung Cancer 2023...

Lung Cancer

Expert Point of View: Upal Basu Roy, PhD, MPH

Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...

Lung Cancer

INCREASE Trial: Immunotherapy Plus Chemoradiotherapy Doubles Complete Pathologic Response Rate in NSCLC

The integration of immunotherapy with traditional chemoradiotherapy has significantly increased pathologic complete response rates in patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on...

Lung Cancer

Expert Point of View: Helena Linardou, MD, PhD

Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, was invited to discuss the subgroup analysis of small cell lung cancer (SCLC) in the DS7300-A-J101 trial. She first noted that the antibody-drug conjugate...

Lung Cancer

Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows ‘Robust’ Activity in Refractory Small Cell Lung Cancer

The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...

Lung Cancer

Iruplinalkib Demonstrates Improved Efficacy and Tolerance vs Crizotinib in ALK Inhibitor–Naive, Advanced ALK-Positive NSCLC

The novel ALK tyrosine kinase inhibitor iruplinalkib has demonstrated potential for a difficult-to-treat subset of patients with non–small cell lung cancer (NSCLC), according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 A...

Lung Cancer
Genomics/Genetics

Expert Point of View: Roy S. Herbst, MD, PhD

Roy S. Herbst, MD, PhD, cautioned that although FLAURA2 is a positive result, most patients will still develop drug resistance. “The result is really good and clearly positive, but if you look at the survival curves, there is still early overlap in a way that makes it unlikely this combination will ...

Lung Cancer
Genomics/Genetics

FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC

First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...

Lung Cancer

Taiwan National Lung Cancer Early Detection Screening Program Targets Smokers and Nonsmokers With Family History

Findings from the Taiwan National Lung Cancer Early Detection Program have shown that lung cancer screening by low-dose computed tomography (CT) can detect tumors at an early-enough phase to allow for effective intervention. In a recent analysis, 85% of tumors detected by screening were stage 0 or...

Lung Cancer

Extended Pleurectomy Decortication Plus Chemotherapy for Mesothelioma Linked to Increased Risk of Death in MARS-2 Trial

The results of a recent study from the United Kingdom could spell the end of a long-standing treatment strategy for mesothelioma, according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer.1 When combined with...

Lung Cancer

Highlights From the 2023 World Conference on Lung Cancer

The management of lung cancer and other thoracic malignancies has evolved significantly over the past decade. Thanks to many scientific advancements in the field, new therapeutic options, and improvements in screening and early detection, more patients are being cured, and many others are living...

Lung Cancer

Small Study Identifies Safe, Effective Radiation Dose to Add to Neoadjuvant Chemotherapy and Durvalumab

Low-dose radiotherapy in combination with the monoclonal antibody durvalumab and chemotherapy as neoadjuvant therapy was well tolerated in patients with potentially resectable stage III non–small cell lung cancer (NSCLC), according to a small study conducted in China and presented at the...

Lung Cancer

Expert Point of View: Justin F. Gainor, MD

Discussant of the abstract on the ASTRUM-004 trial, Justin F. Gainor, MD, emphasized the significant, positive improvements in survival among patients randomly assigned to receive the PD-1 inhibitor serplulimab vs placebo. Dr. Gainor is Director of the Center for Thoracic Cancers Program, Director ...

Lung Cancer

ASTRUM-004: Serplulimab Plus Chemotherapy as First-Line Treatment of Advanced Squamous Non–Small Cell Lung Cancer

A novel treatment approach to squamous non–small cell lung cancer (NSCLC) may improve the prognosis for patients with previously limited treatment options, according to data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.1 Findings from ...

lung cancer

Jarushka Naidoo, MHS, MBBCh, on Lung Cancer: Practice-Changing Advances Reported at ESMO 2023

Jarushka Naidoo, MHS, MBBCh, of the Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, discusses some of the key lung cancer data presented at the ESMO Congress 2023: CheckMate 77T, a phase III study of nivolumab, chemotherapy, and surgery for previously untreated resectable stage II–IIIB NSCLC; the ALINA study of alectinib vs chemotherapy in patients with early-stage ALK-positive NSCLC; and overall survival data from KEYNOTE-671, which established the role of chemoimmunotherapy and pembrolizumab. Dr. Naidoo also reviews data in small cell lung and thymic cancers.

Lung Cancer

Adding Pembrolizumab to Chemotherapy for Previously Untreated Advanced Pleural Mesothelioma

As reported in The Lancet by Chu et al, a phase III trial conducted in Canada, Italy, and France showed that the addition of pembrolizumab to chemotherapy improved survival in previously untreated patients with advanced pleural mesothelioma. Study Details In the multicenter open-label trial, 440...

Lung Cancer

Perioperative Durvalumab Improves Surgical Outcomes in Resectable NSCLC: Phase III AEGEAN Trial

The addition of durvalumab to neoadjuvant chemotherapy led to higher rates of R0 resections and posed no apparent impediments to successful surgery for resectable non–small cell lung cancer (NSCLC), according to findings from the randomized phase III AEGEAN trial presented at the International...

lung cancer

Benjamin Besse, MD, PhD, on NSCLC: Safety and Efficacy Data on Novel Bispecific Antibody

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses new findings on AZD7789, which targets PD-1 and TIM-3, in patients with stage IIIB–IV non–small cell lung cancer (NSCLC) with previous anti–PD-L1 therapy. This bispecific antibody showed manageable safety and preliminary efficacy at tolerable doses (Abstract 1313MO).

Lung Cancer

FDA Approves Next-Generation Tyrosine Kinase Inhibitor Repotrectinib for ROS1-Positive NSCLC

On November 15, 2023, the U.S. Food and Drug Administration (FDA) approved the next-generation tyrosine kinase inhibitor repotrectinib (Augtyro) for the treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). According to the American Lung Association, the ROS1 ...

lung cancer
genomics/genetics

Benjamin Besse, MD, PhD, on EGFR-Mutated NSCLC: Update on Patritumab Deruxtecan in Previously Treated Disease

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses phase II findings from the HERTHENA-Lung01 study, which showed patients with previously treated EGFR-mutated non–small cell lung cancer may benefit from the antibody-drug conjugate patritumab deruxtecan after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy (Abstract OA05.03). The phase III HERTHENA-Lung02 trial is ongoing.

Lung Cancer

Osimertinib With or Without Chemotherapy in EGFR-Mutant Advanced NSCLC

As reported in The New England Journal of Medicine by Planchard et al, the phase III FLAURA2 trial has shown superior progression-free survival with osimertinib plus platinum-based chemotherapy vs osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...

Lung Cancer

Screening for Lung Cancer: Much Work Remains to Be Done

Remarkable progress has been made in the treatment of lung cancer in the past 10 to 15 years; it is therefore not surprising that lung cancer mortality in the United States is declining consistently, at the rate of 2% to 4% annually in recent years. Long-term survival is possible even for patients...

Lung Cancer

Results of PACIFIC Trial Being Replicated in Real-World Settings

Real-world outcomes often fall short of those achieved in clinical trials, but this is apparently not so for patients receiving chemoradiotherapy plus consolidation with durvalumab in unresectable stage III non–small cell lung cancer (NSCLC). The robust results achieved in the phase III PACIFIC...

Lung Cancer

Addition of Tumor Treating Fields Therapy to Standard Systemic Therapy Improves Survival in Metastatic NSCLC after Progression on Platinum-Based Therapy

In a phase III trial (LUNAR) reported in The Lancet Oncology, Ticiana Leal, MD, Winship Cancer Institute at Emory University, and colleagues found that the addition of Tumor Treating Fields (TTFields) therapy to standard systemic therapy improved overall survival in patients with metastatic...

Advertisement

Advertisement

Advertisement